Pharming Group Nv · EURONEXT:PHARM
Pharming Group Nv — Shareholder Meeting (March 2025)
19 slides from Pharming Group Nv's shareholder meeting presentation, Mar 4, 2025
Slide 1: Extraordinary General Meeting of Shareholders
Pharming Group N.V. Extraordinary General Meeting of Shareholders March 4, 2025 NASDAQ: PHAR | EURONEXT Amsterdam: PHARM
Slide 2: 1. Opening
DISCUSSION ITEM AGENDA ITEMS: 1/5 1. Opening
Slide 3: Agenda
Agenda 1. Opening 2. Appointment Executive Director and Chief Executive Officer (voting item) Proposal to appoint Fabrice Chouraqui, upon binding nomination of the Board of Directors, as Executive Director and Chief Executive Officer for a period of four years 3. Remuneration Executive Director and
Slide 4: 2. Appointment Executive Director and Chief Executive Officer
VOTING ITEM AGENDA ITEMS: 2/5 2. Appointment Executive Director and Chief Executive Officer (voting item)
Slide 5: Jabine van der Meijs
Jabine van der Meijs Non-Executive Director, Chairperson of the Corporate Governance Committee, Member of the Audit Committee and Member of the Remuneration Committee
Slide 6: Fabrice Chouraqui, CEO elect: Introduction
Fabrice Chouraqui CEO elect Introduction
Slide 7: 2. Appointment
2. Appointment Executive Director and Chief Executive Officer • The Board of Directors proposes by way of a binding nomination, the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a period of four years effective as of the closing of the EGM and expiring at
Slide 8: Agenda item 2 voting results
Agenda item 2. % Pharming Appointment Executive Director and Chief Executive Officer For 67,012,446 Against 498,720 Abstain 2,411,644 Against | 0.74%
Slide 9: 3. Remuneration Executive Director and Chief Executive Officer
VOTING ITEM AGENDA ITEMS: 3/5 3. Remuneration Executive Director and Chief Executive Officer (2 voting items)
Slide 10: Steven Baert
Steven Baert Non-Executive Director, Chair of the Remuneration Committee and Member of the Corporate Governance Committee
Slide 11: 3.1. Approve specific components of the remuneration package
VOTING ITEM AGENDA ITEMS: 3/5 3.1. to approve specific components of the remuneration package for Mr. Chouraqui, as Executive Director and Chief Executive Officer
Slide 12: 3. Remuneration
3. Remuneration Executive Director and Chief Executive Officer Remuneration package Fabrice Chouraqui as Executive Director and Chief Executive Officer: • Annual base salary: USD 750,000 gross (reference year: 2025) • Annual Short-Term Incentive Plan in cash (“STI”): target score to be set at 75% of
Slide 13: 3. Remuneration: proposal components
3. Remuneration Executive Director and Chief Executive Officer 3.1 proposal to approve the following components of the remuneration package for Mr. Chouraqui, as Executive Director and Chief Executive Officer: i. the grant of a severance payment equal to 200% of his fixed annual base salary, in case
Slide 14: Agenda item 3.1 voting results
Agenda item 3.1 % Pharming Approval for components of the remuneration package for Mr. Chouraqui, as Executive Director and Chief Executive Officer For 66,006,071 Against 1,274,735 Abstain 2,642,004 Against ] 1.89%
Slide 15: 3.2. Authorize the Board of Directors
VOTING ITEM AGENDA ITEMS: 3/5 3.2. to authorize the Board of Directors as the company body authorized: (a) to grant and issue to the CEO (i) the restricted ordinary shares pursuant to the LTI and (ii) the compensation for the forfeited equity awards in shares; and (b) to exclude any pre-emptive righ
Slide 16: Agenda item 3.2 voting results
Agenda item 3.2 % Pharming Authorization of the Board of Directors for a period of eighteen (18) months For 66,629,952 Against 858,303 Abstain 2,434,555 Against | 1.27%
Slide 17: 4. Any other business
DISCUSSION ITEM AGENDA ITEMS: 4/5 4. Any other business (discussion item)
Slide 18: 5. Closing
5. Closing www.pharming.com | investor@pharming.com NASDAQ: PHAR | EURONEXT Amsterdam: PHARM Bloomberg: PHAR.AS
Slide 19: www.pharming.com
www.pharming.com NASDAQ: PHAR | EURONEXT Amsterdam: PHARM